Press Release5 Minute ReadApr | 20 | 2021
Xingbin Ai, PhDWe hope to leverage this knowledge for future development of markers and treatment strategies for infant diseases that involve abnormalities in these cells.
BOSTON – Recent research links certain cells that line the human airway with different infant diseases. The work, which is published in Cell Reports and was led by investigators at Massachusetts General Hospital (MGH), could lead to new prevention and treatment strategies for these conditions.
The human airway—from the windpipe to the lungs—is lined with epithelial cells, including a type called pulmonary neuroendocrine cells (PNECs) that communicate with the nervous system and secrete different factors and hormones. Increased numbers and clusters of PNECs have been observed in various breathing-related illnesses, but the cells’ roles in health and disease are unclear. To better understand PNECs and their effects in the body, researchers analyzed lung and airway tissues from humans and mice.
The scientists were surprised to find that PNECs are much more varied than previously described. In fact, it appears that the airway harbors three distinct types of PNECs. Some PNECs express a protein called tubulin beta 3 class III (TUBB3), and this protein is required for protrusions involved in communication between the cells and their environment. Therefore, PNECs with and without TUBB3 may have different sensing mechanisms. Also, higher numbers of certain PNECs were present in autopsied tissues from children who had died from diseases such as sudden infant death syndrome and neuroendocrine hyperplasia in infancy, a rare lung disorder of unknown cause.
“We are currently studying how different subpopulations of PNECs differ in their function,” says senior author Xingbin Ai, PhD, a pulmonary disease specialist in the Department of Pediatrics at MGH. “We hope to leverage this knowledge for future development of markers and treatment strategies for infant diseases that involve abnormalities in these cells.”
This work was supported by the National Institutes of Health.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.
Mass General Brigham researchers found that getting vaccinated on the early side of the recommended window was best for transferring maternal antibodies to the fetus.
The researchers found that damage to the heart is driven by a different immune response than the anti-tumor one, suggesting that this serious complication could one day be managed without halting cancer therapy.
Researchers from Mass General have found that engaging in recommended weekly amounts of physical activity—either concentrated in one to two days or spread throughout the week—may reduce the risk of a broad range of conditions.
Researchers found that treating lab models of PD with low doses of carbon monoxide—comparable to the exposure experienced by people who smoke—protected against neurodegeneration and prevented the accumulation of a key disease-related protein
A novel educational program for clinicians provided a foundation about climate change and the impact of fossil fuel-related pollution on individual health.
